Loading clinical trials...
Loading clinical trials...
Phase II Study of XNW5004 in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)
Conditions
Interventions
XNW5004 tablets
Locations
1
China
Beijing Cancer Hospitial
Beijing, Beijing Municipality, China
Start Date
February 14, 2026
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2028
Last Updated
April 22, 2026
Lead Sponsor
Evopoint Biosciences Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions